Corneal Epithelial Alterations Associated With CDK4/6 Inhibitor Therapy in Hormone Receptor-Positive Breast Cancer

The authors aimed to investigate whether CDK4/6 inhibitor therapy in hormone receptor-positive breast cancer patients is associated with corneal epithelial alterations, independent of aromatase inhibitor exposure and tear film dysfunction. Their findings revealed a significantly higher prevalence and severity of punctate epitheliopathy and vortex keratopathy in patients receiving CDK4/6 inhibitors compared to those on aromatase inhibitors alone or controls, suggesting a direct cytostatic effect on the corneal epithelium. Despite low symptom scores among patients, the study highlights the need for proactive corneal surface evaluation during CDK4/6 inhibitor treatment.